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ABSTRACT
In human prostate cancer (PCa), the neuroendocrine cells, expressing the 
prostate cancer stem cell (CSC) marker CD44, may be resistant to androgen ablation 
and promote tumor recurrence. During the study of heterogeneity of the highly 
aggressive neuroendocrine PCa cell lines PC3 and DU-145, we isolated and expanded in 
vitro a minor subpopulation of very small cells lacking CD44 (CD44neg). Unexpectedly, 
these sorted CD44neg cells rapidly and spontaneously converted to a stable CD44high 
phenotype specifically expressing the CD44v8-10 isoform which the sorted CD44high 
subpopulation failed to express. Surprisingly and potentially interesting, in these 
cells expression of CD44v8-10 was found to be induced in stem cell medium. CD44 
variant isoforms are known to be more expressed in CSC and metastatic cells than 
CD44 standard isoform. In agreement, functional analysis of the two sorted and 
cultured subpopulations has shown that the CD44v8-10pos PC3 cells, resulting from 
the conversion of the CD44neg subpopulation, were more invasive in vitro and had 
a higher clonogenic potential than the sorted CD44high cells, in that they produced 
mainly holoclones, known to be enriched in stem-like cells. Of interest, the CD44v8-10 
is more expressed in human PCa biopsies than in normal gland. The discovery of 
CD44v8-10pos cells with stem-like and invasive features, derived from a minoritarian 
CD44neg cell population in PCa, alerts on the high plasticity of stem-like markers and 
urges for prudency on the approaches to targeting the putative CSC.
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INTRODUCTION
Prostate cancer (PCa) is primarily treated with 
removal of androgens; however, in the case of primary 
metastatic PCa, androgen deprivation therapy initially 
reduces tumor burden, but ultimately the disease will 
recur in most cases [1]. Literature data on PCa have 
demonstrated tumour-suppressive functions of TLR3, a 
receptor for viral double-stranded RNA (dsRNA), and 
it has been shown that poly(I:C), a synthetic analog of 
dsRNA, exerts both a direct apoptotic effect on TLR3-
expressing cancer cells and anticancer immune stimulation 
[2, 3]. We have previously demonstrated that poly(I:C) 
induces apoptosis in the androgen-dependent PCa cell 
line LNCaP in vitro [4] and in vivo [5], whereas only a 
weak apoptotic effect is observed in the more aggressive 
mCRPC cells PC3 and DU-145 [6]. These cell lines 
are the prototype of prostatic small cell neuroendocrine 
carcinoma (SCNC), in which neuroendocrine (NE) 
features are associated with the expression of the stem/
progenitor cell marker CD44 [7]. The hyaluronan receptor 
CD44 is a single pass transmembrane glycoprotein 
involved in cell-cell and cell-matrix adhesion. It has a 
relevant role in lymphocyte homing, inflammation, cell 
migration and tumour metastasis [8]. CD44 is regarded as 
a marker of normal prostatic epithelium stem cells as well 
as cancer stem cells (CSCs) [9] and CD44high PCa cells are 
more tumorigenic and metastatic than the isogenic CD44-
negative (CD44neg) PCa cells [10].
To date, there is still no gold-standard to define and 
identify CSCs in PCa. Traditionally, researchers have 
isolated prostate CSCs by identifying a combination of 
cell surface markers, namely CD44 [10], CD133 [11] and 
α2β1 integrin [12]. However, PCa is a very heterogeneous 
tumour in which the CSC pool contains heterogeneous 
tumorigenic subsets that possess distinct tumour-initiating 
properties [13].
The present study was initially aimed at testing 
whether, within the bulk population of very aggressive 
PCa cell lines, a subset of CSCs could be selected on 
the basis of different resistance to poly(I:C)-induced 
apoptosis in analogy with recent data on breast cancer 
[14]. Unexpectedly, cell separation experiments based 
on CD44 expression have led us to the identification 
of a novel cell subpopulation endowed with functional 
stem like traits. Here we show that in PC3 and DU-145 
cell lines this scanty subpopulation includes very small 
CD44neg cells that rapidly convert to CD44high cells which 
have high clonogenic and invasive potential and express 
a specific CD44 variant 3 isoform, characterized by 
variant exons v8-10 (CD44v8-10), crucial for metastatic 
feature. Interestingly, CD44v isoforms are expressed in a 
range of cancers mainly in advanced stages [15] and are 
associated with stem [16] and metastatic [17] features. 
In particular, CD44v8-10 is a specific CSC marker of 
head and neck [18] and gastric cancers [19] and its low 
expression in normal tissues makes it an ideal target to 
fight CSCs. Moreover, a close relationship between 
CD44v8-10 expression and increased metastatic potential 
has been also demonstrated both in breast [20] and bladder 
cancers [21]. The high tumorigenic potential of the so far 
neglected CD44neg subpopulation of PCa cell lines, besides 
representing an advancement in the dissection of PCa 
heterogeneity/lineage, strongly highlights the importance 
of adopting self renewal and metastatic parameters 
rather than the canonical cell surface markers in the 
characterization of PCa stem cells.
RESULTS
Poly (I:C) treatment selects CD44-negative 
subpopulation
We have previously demonstrated that the androgen-
independent cell line PC3 is resistant to poly (I:C)-induced 
apoptosis [6]. To establish whether such resistance could 
be correlated to differences in CD44 expression, we 
treated PC3 cells with 25 μg/ml poly (I:C) for increasing 
times up to 4 days and analyzed the composition of the 
cell population by flow cytometry using an anti-CD44 
antibody that recognizes both standard and all CD44 
variant isoforms. We observed that poly(I:C) treatment 
resulted in an increased percentage of CD44neg cells 
(only 2-4% in control sample) up to 5-fold in 3 days 
treatment (Figure 1A) accompanied by a shift to a median 
fluorescence intensity (MFI) higher than the control 
(Figure 1B). The population lacking CD44 protein was 
very small in size, i.e.~ 60% of these components ranged 
between 3-7 μm and the others between 7-15 μm (data not 
shown).
Most of the CD44neg-enriched population resulting 
from poly (I:C) treatment is included in a size area 
generally comprising the debris in flow cytometry analysis 
based on forward scatter vs side scatter. Thus, to verify 
our data excluding debris, we treated with poly (I:C) PC3 
cells infected with TWEEN-EGFP lentiviral vector and 
sorted only the GFP-positive cell population. In addition, 
to analyze CD44 expression also in cells selected after 
chemotherapeutic agent, we used docetaxel, which is 
considered standard first-line therapy in prostate cancer 
cases following resistance to androgen deprivation therapy. 
Therefore, we treated the PC3-GFP cells with poly (I:C) 
or with the docetaxel for 72 hours and flow cytometry 
analysis confirmed that a high increment of CD44neg 
population was elicited by both treatments, although less 
apparent in docetaxel-treated samples (Figure 1C).
Poly (I:C)-enriched CD44-negative cells give rise 
to CD44-positive cells
In order to explore the biological properties of the 
cell populations resulting from poly (I:C) treatment, single 
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PC3 GFP cell suspensions were obtained and sorted by 
FACS into CD44high and CD44neg cells. The purity of 
these cell populations was generally >95% as revealed by 
post-sort analysis and dot plot data show the small sized 
CD44neg population (Figure 2A). Surprisingly, 2 days after 
sorting, the vast majority (75%) of CD44negGFP cells gave 
rise to a population expressing membrane-CD44 protein 
(Figure 2B) and showing similar size to sorted CD44high 
cells (not shown).
CD44-negative cells sorted from PC3 and DU-
145 cell lines spontaneously convert to highly 
positive CD44 cells
We next explored whether the minoritarian CD44neg 
population in parental PC3 cell line could also undergo 
spontaneous conversion. To this aim, we isolated pure 
(average, >95%) populations of CD44high and CD44neg 
cells fractionated by FACS directly from PC3 cultures. 
Cells from these two PC3 subpopulations were seeded 
immediately after sorting and monitored by cytometric 
analysis for CD44 expression over the subsequent 11 
days. Purified CD44high cells remained a pure CD44high 
population, whereas CD44neg cells gave rise to a CD44-
positive (CD44+) cell population that progressively 
increased in percentage and in mean fluorescence intensity, 
in fact, the initial 4% ratio of contaminant CD44+ cells in 
the CD44neg fraction immediately after sorting (0 d) rose to 
~ 60% just after 1 day, restoring almost the initial CD44high 
expression profile in 6 days (Figure 3A and 3B). Of note, 
neither cell proliferation or cell death occurred in the first 
24 hours post sorting, since the number of living cells 
plated remained constant (not shown), meaning that a fast 
conversion from CD44neg to CD44+ happens and not the 
selection of a specific cell population.
In addition, similar FACS experiments were 
performed on DU-145 cells to test whether the fast 
conversion from CD44neg to CD44high cells was shared by 
another androgen-insensitive PCa cell line. As shown in 
Figure 3C, also CD44neg subpopulation sorted from DU-
145 spontaneously converted to CD44high.
Cells derived from CD44-negative subpopulation 
show higher proliferative rate and clonogenic 
potential than cells derived from CD44high 
population
Data from literature described CD44-positive cells 
as stem-like and more tumourigenic cells in prostate cancer 
[10]. Our results on the conversion of CD44neg sorted cells 
to CD44high led us to hypothesize that a more aggressive 
cell population may arise from components of the CD44neg 
cells. Therefore, in order to investigate and compare the 
functional properties of CD44neg and CD44high cells, we 
performed growth curves of cells derived from both cells 
subpopulations by MTT assay. Data in Figure 3D show 
that CD44neg-derived cells have an enhanced proliferation 
ability than CD44high and parental PC3 cells. Moreover, 
we assessed their self renewal potential by evaluating 
their respective clonogenic potential in limiting dilution 
assays, as described in Materials and Methods. Although 
CD44neg and CD44high cells showed a similar clonogenic 
Figure 1: Enrichment in CD44-negative cell subpopulation resulting from Poly(I:C) stimulation. (A) CD44 expression 
was evaluated in PC3 cells treated with 25 μg/ml poly (I:C) for 2, 3 and 4 days, calculated as percentage of total live cells. Each data point 
is the mean ± SEM of three independent experiments *p < 0.05; **p < 0.01, ***p < 0.001, Student’s paired t-test. (B) Representative flow 
cytometry histogram overlay of live cells before (broken line) and after 72 hours poly (I:C) treatment (continuous line). Poly (I:C) induces 
an increase of CD44neg cells (M1) and a decrease of CD44-positive population (M2). The grey histogram represents the isotype control 
APC-labeled IgG2B. Cells were gated using sytox blue stain to exclude dead cells. (C) Percentage of CD44-negative cells after 25 μg/ml 
poly (I:C) or with 20 nM docetaxel in PC3-GFP sorted population (C) and in GFPlow cells. Data represent the mean ± SEM derived from 
three independent experiments *p < 0.05; **p < 0.01; ***p < 0.001, Student’s paired t-test.
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potential in primary clonogenic assay (Figure 3E, 0 d), 
after culturing for 28 days, the progeny of CD44neg cells 
exhibited a significantly higher clonogenic potential than 
that derived from CD44high cell population which resulted 
in a decreased clonogenicity (Figure 3E, 28 d). In order 
to clarify the different clonogenic potential of two cell 
populations, we analyzed the clone types in primary 
clonogenic assay, since the formation of holoclones has 
been adopted as a surrogate stem cell assay, particularly 
in prostate cancer [22]. In primary clonogenic assay, 2 
weeks after plating, 63% ± 1.1 of clones generated by 
sorted CD44neg cells developed into typical holoclones, 
22% ± 1.4 formed meroclones and 15% ± 1.4 formed 
paraclones. Conversely, the clones derived from sorted 
CD44high cells were mostly meroclones (46% ± 5.6) and 
only 27% ± 1.6 were represented by holoclones (Figure 
3F). These results explain the decreased clonogenicity 
of CD44high progeny shown in Figure 3E, because only 
the holoclones are able to generate the full spectrum of 
clonal heterogeneity thus ensuring maintenance of the 
pool of stem-like cells. Furthermore, we verified the 
holoclone ability to regenerate the full spectrum of clonal 
heterogeneity selecting 7 holoclones and 3 meroclones 
derived by CD44high - and CD44neg-primary clonogenic 
assay. In line with previous evidence [23] holoclones, but 
not meroclones, gave rise to all three types of clones in 
the secondary clonogenic assay (Supplementary Figure 1).
The progeny of CD44-negative PC3 
subpopulation specifically expresses CD44 v8-10 
variant isoform and the epithelial splice factor 
ESRP-1
The progeny of CD44neg cells after 2 days in 
culture expressed as much CD44 as the cells derived 
from the CD44high subpopulation (Figure 3). However, 
Figure 2: Change in CD44 expression in the two populations sorted from poly (I:C)-treated PC3 cells. (A) Presorting 
PC3-GFP CD44high and CD44neg subset distribution after three-day treatment with poly(I:C) (left panel) and CD44high and CD44neg subset 
purity after sorting from poly(I:C)-treated PC3-GFP (right panels). (B) PC3-GFP cells were treated 72 hours with poly (I:C) and sorted for 
CD44 expression. The histograms represents the percentage of CD44+ cells in CD44negGFP and CD44highGFP sorted PC3 immediately after 
sorting (0 d) and two days (2d) after culturing. Cells were gated using sytox blue stain to exclude dead cells. n=3 mean ± S.E.M **p < 0.01, 
Student’s paired t-test.
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since the CD44 variant isoforms have been linked to 
subpopulations endowed with stem cell potential, to 
enhanced metastatic ability and a poor prognosis in several 
types of cancer [24, 25], we decided to investigate whether 
the functionally distinct cell populations generated by 
CD44neg and CD44high cells expressed different CD44 
splice variant isoforms at the mRNA and protein level. 
We first performed semiquantitative RT-PCR from both 
PC3 CD44neg- and CD44high-derived cells by designing 
PCR primers in constant exons 5 and 19 (p1 and p2 in 
Figure 3: Time course of CD44 expression in CD44neg- and CD44high-sorted cells, proliferation rate and clonogenic 
potential. (A) Percentage of CD44+ cells in CD44neg and CD44high-sorted PC3 populations immediately after sorting (0 d) and for the 
indicated times after culturing. n=3 mean ± S.E.M **p < 0.01, Student’s paired t-test. (B) Representative histograms of CD44 expression in 
CD44neg and CD44high cell subpopulations cultured for the indicated times. The dotted histograms represent the fluorescence of the APC-
labeled isotype control IgG2B, the continuous histograms indicate the fluorescence of APC-labeled CD44 antibody. (C) Percentage of 
CD44+ cells in CD44neg and CD44high-sorted DU-145 populations immediately after sorting (0 d), 1 and 2 days after culturing. Cells were 
gated using sytox blue stain to exclude dead cells. Results represent the mean from three independent sorting experiments with S.E.M. ***p 
< 0.001, Student’s paired t-test. (D) Growth curves of cells derived from CD44neg and CD44high cells assayed by MTT. Results represent 
the mean ± S.E.M of two independent experiments in quadruplicate. (E) Assessment of clonogenic potential by limiting dilution assay in 
CD44neg and CD44high PC3 subpopulations immediately after cell sorting (0 d) and in two expanded populations cultured up to 28 days. 
Three clonogenic assays performed from three independent sorting experiments were carried out (*p < 0.05). (F) The clone typing of 
primary clonogenic assays of the two PC3 sorted populations is shown. Data are from three independent sorting experiments. All the data 
were analyzed by Student’s paired t-test. n=3 mean ± S.E.M.
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Figure 5A), flanking the variable region of the CD44 
gene (Figure 4A). We found a 763-bp product, probably 
corresponding to CD44 variant 3, containing exons 
v8, v9 and v10 (CD44 v8-10), exclusively expressed in 
the progeny of CD44neg cells; while the 367-bp product 
corresponds to the CD44s mRNA (Figure 4A). In order 
to evaluate the CD44 v8-10 mRNA levels in the two 
populations, we performed quantitative RT-PCR (qRT-
PCR) analysis with p1 and p3 primers indicated in Figure 
4A. Our results show a 20-fold higher expression of CD44 
v8-10 mRNA in PC3 CD44neg-derived cells compared to 
CD44high-derived population 21 days after sorting (Figure 
4B). An enriched expression of CD44 v8-10 transcript was 
also observed in CD44neg-derived DU-145 cells, although 
at less extent (Supplementary Figure 2A). Since primers 
p1 and p3 amplify all the CD44 variants that contain the 
v8 exon, not only CD44v8-10, we verified the sequence 
of variant exons v8, v9 and v10 by DNA sequencing 
using primers p1 and p4 (Figure 4A), as described in 
Supplementary Methods.
We therefore examined the expression of epithelial 
splicing regulatory protein 1 (ESRP1), which regulates 
alternative splicing of CD44 mRNA [26]. As expected, 
we observed that PC3 cells highly expressing CD44v8-10 
showed an apparent level of ESRP1 mRNA compared to 
the progeny of CD44high sorted cells (Figure 4B). Given 
that ESRP1 is a target of zinc finger E-box binding 
homeobox 1 (ZEB1) repression, we also found a very 
low ZEB1 expression in ESRP1-highly positive PC3 
subpopulation (Figure 4B).
We next used an antibody specific to CD44v8-10 
to assess the differential expression of this variant at the 
protein level by flow cytometry. About 90% of the PC3 
CD44neg-derived cells was found to express CD44v8-10 
protein, while only 2% of CD44high-derived cells 
expressed this CD44 variant isoform when cultured in 
10% FCS medium (Figure 4C). The higher CD44v8-10 
protein expression in the progeny of CD44neg compared 
to CD44high -derived cells was confirmed by indirect 
immunofluorescence analysis (Figure 4E). Surprisingly 
and potentially interesting, when the CD44high -derived 
cells and the parental PC3 cells were maintained in stem 
medium for four weeks, they displayed high levels of 
CD44v8-v10 membrane protein (Figure 4C), suggesting 
that in stem conditions CD44v8-10 expression is strikingly 
induced. The representative dot plot of the different cell 
populations is shown in Figure 4D.
Cell cycle analysis by propidium iodide (PI) 
staining revealed that the proliferation of CD44v8-v10-
positive PC3 cells is higher than CD44v8-v10-negative, 
being the former 62.2% actively cycling (S + G2/M 
phases) compared to 49.6% of the CD44v8-v10-negative 
population (Figure 4F).
Moreover, we investigated the amount of 
CD44v8-10 membrane protein expressed by CD44neg-and 
CD44high-derived populations from DU-145 cells. Values 
of membrane CD44v8-10 protein mirrored that obtained 
in PC3 cells (Supplementary Figure 2B, 2C).
CD44 v8-10 expression induces increased 
motility and invasiveness in PC3 cells
Since we showed that the whole CD44neg-derived 
PC3 population converts to CD44v8-10-expressing 
population, whereas CD44high-derived population does 
not express this variant, from here onwards we decided 
to name the first population as CD44v8-10pos PC3, while 
the latter one as CD44v8-10neg PC3 cells. Therefore, we 
aimed to investigate the role of CD44v8-10 variant in 
biological features of CD44v8-10pos PC3 cells. CD44v8-10 
was found to define tumour cells with marked metastatic 
potential [17, 21], thus we characterized migration and 
invasion capability of the two PC3 subpopulations by 
using the transwell migration/invasion assays. Our data 
showed a considerably stronger migration and especially 
invasion ability of CD44v8-10pos PC3 cells compared to 
CD44v8-10neg PC3 cells (Figures 5A and 5B). Moreover, 
activation of proteolytic enzymes necessary to controlled 
degradation of extracellular matrix is involved in tumour 
cell invasion. Among these proteases, the Plasminogen 
activators (PA)/plasminogen system controls proteolysis 
thus, facilitating tumour invasiveness and growth [27]. 
Therefore, the presence of PAs in the conditioned media 
of two subpopulations was evaluated by zymography. 
Lytic bands appeared in the casein underlay with a mol 
wt of about 55 kDa, which is the usual size of human 
urokinase plasminogen activator (uPA) (Figure 5C). The 
lytic zones were plasminogen dependent. In accordance 
with their higher invasiveness, CD44v8-10pos PC3 cells 
secreted higher levels of uPA compared to the CD44v8-
10neg population (Figures 5C and 5D).
By using a specific siRNA targeting v9 exon, we 
demonstrated a key role of CD44v8-10 variant in these 
invasive features (Figure 5E). CD44v8-10 protein down-
regulation after specific siRNA transfection ranged 55-
60%, as shown in Figure 5F and 5G.
CD44v8-10 expression in human PCa samples
Although several articles agreed on the fact that a 
loss of CD44 expression during human prostate cancer 
progression correlated with higher tumor grade and distant 
metastasis, recently CD44v6 [28] and v10 [29] have been 
proposed as useful biomarkers predicting poor outcome 
following radical prostatectomy for localized PCa. Stated 
these confusing results on CD44 variants expression in 
human PCa samples, we analyzed the expression pattern 
of CD44v8-10 in 30 normal prostate and in prostate cancer 
tissues from 60 patients using immunohistochemistry. 
Notably, our analysis reveals that CD44v8-10 reactivity 
in prostate cancers changes in intensity and distribution 
when compared to normal prostate tissues. CD44v8-10 
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Figure 4: CD44v8-10 expression in CD44neg- and CD44high -derived PC3 populations. (A) Schematic diagram of human 
CD44 gene structure showing alternatively spliced variant exons v8-10 in white boxes and constant exons in grey boxes. CD44v8-10 
comprises all constant exons and variant exons 8, 9 and 10, while CD44s contains only constant exons. CD44 variant mRNAs were 
amplified by PCR using the general primers p1 and p2 that can amplify both CD44s (367 bp) and CD44v (763bp). #1, PC3 CD44neg 
progeny;. #2, PC3 CD44high progeny;. #3 parental PC3. (B) qRT-PCR analysis of CD44v8-10, ESRP1 and ZEB1 mRNA in PC3 cells 
derived from CD44neg and CD44high cell populations 2 and 21 days after sorting. Primers used for qRT-PCR are described in Supplementary 
Methods. Data are expressed as fold increase in induction of different gene expression calculated by comparing the values of different 
mRNAs from the progeny of the CD44neg population with those from the progeny of the CD44high population (set arbitrarily at 1). (C) Flow 
cytometry evaluation of the percentage of cells expressing membrane CD44v8-10 isoform in parental PC3 cells and in those derived from 
CD44neg and CD44high cell populations after culturing in growth medium (10% FCS) or four weeks in stem medium. (D) The representative 
FACS plots show the expression of CD44v8-10 in the same conditions of panel C. (E) The representative immunofluorescence analysis 
of CD44v8-10 protein distribution in cultured PC3 indicated subpopulations. (F) Cell cycle analysis of CD44v8-10-positive (CD44pos) 
and CD44-negative (CD44neg) PC3 cells was determined. The percentage of cycling cells (S+G2/M) in CD44pos vs CD44neg is 62.2±0.3 vs 
49.6±1.7, respectively (p<0.001). Data represent the mean ± S.E.M of three independent experiments.
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expression is limited to epithelial cells but restricted to 
the membrane of the basal cell layer in normal glands and 
diffuse to cell membrane of all the displastic cells of the 
HGPIN, while the expression in positive neoplastic cells 
is preferentially extended to the cytoplasm and shows a 
stronger intensity. Residual normal glands in prostate 
samples behaving tumour show the same distribution 
of CD44v8-10 as normal prostate. Tumour glands show 
heterogeneous expression of CD44v8-10 among tumours 
from the same Gleason group (Figure 6). The small 
number of cases examined do not establish an evident 
correlation with Gleason grade or tumour extension 
(evaluated as n° and percentage of tumour involvement on 
at least 12 diagnostic biopsies), although showed a trend 
for increased percentage of CD44v8-10 positive tumours 
with higher Gleason grade group (Table 1).
DISCUSSION
The highly heterogeneous nature of human prostate 
cancer (PCa) both in primary tumour samples and in 
cell lines poses many obstacles to therapy. Tumour 
heterogeneity consists of multiple hierarchies with 
different degrees of differentiation originating from 
heterogeneous cancer stem cell (CSC) pool [13]. It has 
been recently demonstrated that stimulation of TLR3 
by poly(I:C) promotes breast cancer cells toward a CSC 
phenotype in vitro and in vivo, thus potentiating cancer 
recurrences [14]. Given that CD44 has been proven to 
be a candidate marker for PCa stem cells [9], the initial 
aim of the present investigation was to detect whether the 
apoptosis resistance to poly(I:C) treatment can be linked to 
CD44 expression and to heterogeneous PCa phenotypes. 
Unexpectedly, our experimental evidence showed that 
poly(I:C) treatment induced an enrichment in a CD44neg 
population besides a CD44 highly positive (CD44high) 
population. Therefore, to explore the tumorigenic features 
of the two subpopulations selected by poly(I:C), we 
identified and sorted a CD44high and a CD44neg fractions; 
with the latter being composed of particularly small 
cells. We were surprised to find that both CD44neg PC3 
cells sorted after poly(I:C) treatment and CD44neg cells 
from parental PC3 and DU-145 spontaneously converted 
to CD44high cells. Patrawala and coworkers showed that 
Figure 5: PC3 cells expressing CD44v8-10 display a high invasive potential in vitro (A) Transwell migration/invasion assays of PC3 
subpopulations. Data are expressed as fold increase of migration and invasion relative to CD44v8-10neg cells (set arbitrarily at 1). (B) 
Representative images of migration/invasion rate of DAPI-labeled PC3 different populations. (C) Representative zymography of three 
performed, of PA secreted by CD44v8-10pos and CD44v8-10neg PC3 cells. At the indicated times, conditioned media were collected and 
analyzed by casein-agar underlay. The lytic zones were plasminogen dependent and were inhibited by 1 mM amiloride, an uPA-specific 
inhibitor. (D) The same conditioned media were assayed for uPA activity by chromogenic substrate assay. Results represent the mean ± 
SEM of three independently sorted cell subpopulations. (***p < 0.001; **p< 0.01). (E) Transwell migration/invasion assays of CD44v8-
10pos PC3 after specific CD44v8-10 down-regulation by siRNA. Data are expressed as fold decrease of migration and invasion relative 
to CD44v8-10pos cells treated with scramble RNA (set arbitrarily at 1). Three sample of each subpopulation were examined and the cells 
counted in seven fields/sample. (***p < 0.001). (F) Extent of CD44v8-10 knockdown protein after specific CD44v8-10 siRNA or control 
scramble RNA assayed by flow cytometry. All the data were analyzed by Student’s paired t-test. n=3 mean ± S.E.M. (G) Representative 
FACS plots of CD44v8-10 membrane protein expression in CD44v8-10pos PC3 cells four days after specific CD44v8-10 siRNA or control 
scramble RNA treatments.
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CD44high PCa cells were more proliferative, clonogenic, 
tumorigenic, and metastatic than the CD44neg population 
[10]. On the other hand, they also observed the emergence 
of CD44-positive highly tumorigenic clones from a 
pure CD44neg cell population and they explained that 
tumorigenicity as the ability of a minor subset of cells, 
within the CD44neg population, to develop into CD44-
positive cells. Our results are partially in accordance, 
however, the selected population defined “negative” by 
Patralawa represented only the bottom 5% most dimly 
labelled (CD44low), whereas we sorted a subpopulation 
completely lacking CD44 which represents a highly 
dynamic and fast-converting subpopulation that expresses 
CD44 as soon as 24 hours after sorting.
To determine whether the cell populations generated 
by CD44neg and CD44high-sorted cells were functionally 
distinct, in particular whether CD44neg-sorted cells might 
include “stem-like cells” giving rise to CD44high cells, 
we performed biological assays and found that CD44neg-
derived cells displayed a higher proliferative rate as well 
as a higher clonogenic potential than CD44high-derived 
cells, producing mainly holoclones. Our data suggest that 
CD44neg-derived cells contain a higher proportion of self-
renewing cells than CD44high-derived cells. Evidence for 
tumour cell populations that can reversibly shift between 
stem-like and more committed cells, is emerging. It 
has been demonstrated that a subpopulation of normal 
and transformed mammary epithelial CD44low cells 
spontaneously dedifferentiated into CD44high stem-like 
cells [30, 31]. Moreover, a cell population lacking CD44 
and displaying stem-like traits has also been identified 
in head and neck squamous carcinoma [32]. Although 
the conversion from CD44neg into CD44pos cells has been 
observed in primary mesenchymal stem cells of bone 
Figure 6: Expression of CD44v8-10 in normal prostate glands and prostate cancers. Expression of CD44v8-10 in normal 
human prostate gland (n=30) and prostate cancer (n=60). (A) In normal human glands of non-neoplastic prostate, or entrapped in cancer (C 
arrows) and in hyperplastic gland (C arrowhead), the expression of CD44v8-10 is limited to the basal cell layer. (B) CD44v8-10 expression 
of HGPIN varies between a weak positivity of the dysplastic cells in the tuft type to the strong membrane staining of the in situ tumor of 
positive tumor cases (D asterisk). Positive (D, F) and negative (C, E) cases were found in both low group grade (D, E grade 1) or high 
group grade (F, G grade 5) cancers. Original magnification 200x. Human prostate biopsies were immune-stained as indicated in Materials 
and Methods.
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marrow [33], the expression of specific CD44 variants has 
never been explored. Here we show that CD44v8-10 was 
the variant isoform predominantly expressed in CD44neg-
derived cells, whereas it was expressed at lowest levels 
in the CD44high-generated population. CD44v8-10 is 
described in human colon cancer [34], in rat pancreatic and 
mammary cancer cells [35] and up-regulated in primary 
and metastatic tumours but rarely expressed in normal 
tissue. CD44v8-10 is a gastric CSC marker considered 
an ideal target to fight these stem cells [19]. Notably, 
there is evidence that CD44v8-10 enhances the CSC-like 
characteristics also in prostate cancer. It has been reported 
that impairing the splicing of CD44v8-10 attenuates the 
stem-like properties of prostate cancer cells [36].
Moreover, in this paper we show a considerably 
higher migration and invasion ability of CD44v8-10pos 
PC3 cells compared to CD44v8-10neg PC3 cells and the 
down-regulation of CD44v8-10 by siRNA highlights 
the functional role of this variant in PC3 migration/
invasion. In accordance, this variant has been implicated 
in an enhanced lung metastatic potential in breast cancer 
cells [20] while CD44v8-10 over-expression into human 
bladder cancer cells enhances their growth and metastasis 
in vivo [21]. Recently, the poor prognosis of pancreatic 
adenocarcinoma has been correlated with urokinase 
Plasminogen Activator (uPA) increased expression 
and cancer stemness [37]. Accordingly, we observed 
a notably higher production and activity of uPA by the 
progeny of CD44v8-10pos cells. Interestingly, a number 
of studies recently reported that, in addition to epithelial-
mesenchymal transition, the mesenchymal-epithelial 
transition can also induce stem-like properties and increase 
metastatic potential in cancer cells [38]. We observed a 
dramatic expression of ESRP1 in CD44v8-10 highly 
expressing cells. ESRP1 is responsible for the switch from 
mesenchymal CD44s to epithelial CD44v isoforms [26]. 
It has been shown that depletion of ESRP1 in metastatic 
breast cancer cells changed the phenotype of these cells 
from CD44v to CD44s, and resulted in the suppression of 
lung metastasis [20].
Moreover, in the late nineties several authors, by 
using immunohistochemical analysis of human prostate 
cancer specimens, described a down-regulation/loss 
of CD44 expression during human prostate cancer 
progression correlated with higher tumour grade and 
distant metastasis [39–41]. More recently, the expression 
levels of CD44s and all its 9 variants analyzed in surgical 
PCa specimens by qRT-PCR demonstrated that PCa cases 
are characterized by an over-expression of all the variants. 
However, during cancer progression, a loss of expression 
of all CD44 variants was found [42]. Conversely, data 
showed by Tei et al. suggested that over-expression of 
CD44v6 could be a useful biomarker predicting poor 
outcome for localized PCa [28]. In our study, CD44v8-10 
immunostaining on primary tumour samples point out a 
higher CD44v8-10 expression in tumour than in normal 
glands.
In conclusion, given that many CD44v isoforms 
are preferentially expressed on cancer cells and involved 
in tumour progression, these isoforms seem to be better 
CSC markers than CD44s isoform. The identification of a 
CD44v8-10 positive population derived from CD44neg PCa 
cells will open new fields of investigation aimed at finding 
innovative strategies to selectively target the putative 
stem-like subpopulation involved in therapy resistance 
and tumour relapse.
MATERIALS AND METHODS
Cell lines and reagents
PC3 (ATTC n. CRL-1435 Lot n. 61777391) 
and DU-145 (ATTC n. HTB-81 Lot n. 59722255) 
cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA), authenticated by 
ATTC in February 2015 and June 2014, respectively and 
routinely checked for mycoplasma. Cells were cultured 
as previously described [43]. Transfected PC3 cells with 
TWEEN-EGFP lentiviral vector were kindly provided by 
Dr. Haas TL (Istituto Superiore di Sanità, Rome, Italy). 
Poly (I:C) High Molecular Weight (InvivoGen, San Diego, 
CA tlrl-pic-5) and docetaxel (Sigma, O1885) were diluted 
in 3% FCS medium.
Flow cytometry and cell cycle analysis
Cells were detached and incubated with APC-
conjugated CD44 antibody (BD-PharMingen, San Diego, 
CA, USA 559942) or isotype control APC-conjugated 
IgG2B (BD-PharMingen) in PBS BSA 1% (Sigma) 
for 30 minutes on ice prior to flow cytometric analysis. 
Sytox Blue Stain (Life Technologies, Eugene, OR, USA 
Table 1: CD44v8-10 expression in primary tumours with different Gleason grades
Total 
number
Gleason grade 
group 1
Gleason grade 
group 2
Gleason grade 
group 3
Gleason grade 
group 4
Gleason grade 
group 5
N° of primary tumors 60 12 12 12 12 12
N° of CD44v8-10 24 3 3 5 6 5
% positive tumors 40% 25% 25% 42% 50% 42%
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S34857) was added to exclude dead cells. For CD44v8-10 
staining 1x105 cells were incubated with 3 μg/ml anti-
human CD44v9 primary antibody (clone: RV3) (Cosmo 
Bio Co.Ltd, Tokyo, Japan LKG-M001) in PBS 0.2 % BSA 
for 45 minutes at 4°C. Cells were then incubated with the 
secondary antibody APC-labeled Goat anti-Rat IgG (H+L) 
(Invitrogen, Carlsbad, CA, USA A10540) for 30 minutes 
at 4 °C. After washing, cells were assayed using a CyAn 
ADP flow cytometer (Beckman Coulter, Brea, CA, USA) 
and data analyzed employing FCS5 express Software (De 
Novo Software). For cell cycle analysis, after labeling 
for CD44v9, the cells were fixed with 70% ethanol, a 
few drops at a time mixing the cells, and incubated on 
ice for 30 minutes. The cells were centrifuged at 500 x 
g for 10 minutes, washed once in PBS by centrifugation 
and resuspended in 1 ml PBS containing 5 μg/ml of 
propidium iodide. Samples were assayed by CyAn ADP 
flow cytometer and analyzed employing FCS5 express 
Software.
Fluorescence-activated cell sorting (FACS) 
analysis
For sorting experiments, PC3 and DU-145 cells 
were stained with APC-conjugated CD44 antibody (BD-
PharMingen, San Diego, CA, USA). Cell populations were 
analyzed post-sorting to ensure purity of sorting before 
progressing with additional experiments. Apoptotic cells 
were excluded by elimination of cells positive for Fixable 
Viability Stain 780 (FSV780) (BD Biosciences, San Jose, 
CA, USA). FACS was performed with a FACSAria Cell 
Sorter (BD Biosciences, San Jose, CA, USA). Three 
sorting experiments for parental PC3 and DU-145 and two 
experiments for PC3-GFP were performed.
Immunofluorescence
CD44high and CD44neg sorted PC3 cells grown on 35 
mm dishes, fixed 15 min in 4% paraformaldehyde at room 
temperature (RT) and blocked with 10% BSA for 1 hour. 
For CD44v8-10 staining, cells were then incubated with 6 
μg/ml anti-human CD44v9 primary antibody overnight at 
4°C and then incubated 1 hour at RT with 10 μg/ml Goat 
anti-Rat IgG Alexa Fluor 488 secondary antibody (Thermo 
Fisher Scientific). Cells were washed in PBS and stained 
with 600 nM DAPI (Thermo Fisher Scientific). Images 
were acquired by fluorescence light microscope (ZEISS 
Axioskop 2 plus).
Single-cell cloning by limiting dilution
CD44high- and CD44neg-sorted cells were resuspended 
in fresh medium to generate a single-cell suspension with a 
density of 10 cells/ml. Then, 100 μl single-cell suspension 
was dispensed into each well in a 96-well culture plate. 
One day after plating, only the wells that contained 1 
viable cell were selected, excluding the wells with no 
cells or with more than one cell. These single-cell wells 
were maintained in 10% FCS medium and were checked 
after 14 days to establish clonogenic potential. Then, the 
resulting colonies were graded on their morphology.
Migration and invasion assays
To determine the invasive ability of the two PC3 
sorted subpopulation, the transwell membrane filters (8-
μm pore size) (Falcon) were coated with Matrigel (BD 
Biosciences). 200,000 cells were seeded in the upper 
chamber with 1% FCS medium, 20% FCS medium 
was added to the bottom chamber. Following 48 hours 
incubation, the cells were removed from the top surface 
of the membrane. The invasive cells adhering to the 
bottom surface of the membrane were fixed using 4% 
paraformaldehyde (Electron Microscopy Sciences) and 
stained with 600 nM DAPI (Thermo-Fisher Scientific). 
The total number of DAPI-stained nuclei of invading cells 
was counted under a fluorescence microscope by using 
ImageJ software in seven randomly chosen macroscopic 
fields per membrane.
Cell migration was assayed using a Transwell 
migration chamber without Matrigel after 24 hours 
incubation. Each experiment was performed in triplicate 
and was repeated at least three times.
Plasminogen activator (PA) assay, gel 
electrophoresis and zymography
The presence and enzymatic activity of PA were 
assayed as previously described [44]. Experimental details 
were shown in Supplementary Methods.
RNA isolation, RT-PCR, qRT-PCR and siRNA
Total RNA was extracted using TRIzol reagent 
(Invitrogen) and reverse transcription was performed with 
High-Capacity RNA-to-cDNATM Kit (Applied Biosystems-
Thermo Fisher, Waltham, MA, USA 4387406). The 
expression profiling of CD44 isoforms in PC3 and DU 
cells was analysed by semiquantitative RT-PCR. The 
expression levels of CD44v8-10, ESRP1 and ZEB1 were 
determined by Sybr Green qRT-PCR (Bioline, Taunton, 
MA, USA) performed on cDNA using the StepOnePlus™ 
Real-Time PCR System (ThermoFisher). Data were 
analyzed by the ΔΔCt method and GAPDH was used to 
normalize the expression levels of mRNA. siRNAs were 
transfected with RNAiMAX (Invitrogen) for 5 h according 
to the manufacturer’s protocol. The siRNA sequences 
were previously described [36] (synthesized by Bio-Fab 
Research, Rome Italy). The primers used are reported in 
Supplementary Methods.
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MTT assay
PC3 cells were cultured into 96-well plates at a 
concentration of 5×103 cells/well and incubated for 24 h, 
48h and 72h and the assay was performed according the 
manufacturer’s instructions.
Immunohistochemistry for CD44v8-10
The study population consisted of 60 patients with 
PCa who underwent radical prostatectomy or diagnostic 
biopsies in 2017, the mean age of the patients was 71+/-
12 year.
This study was conducted under approval by the 
S. Andrea Hospital (n°Prot. n. 228 SA_2016, 12.12.2016 
RIF. CE: 4208_2016). Histology specimens were 
obtained from the histoteque of Sant’Andrea Hospital 
Pathology Section of Clinical and Molecular Department 
of ‘Sapienza’ University of Rome, among the PCa blocks. 
60 cases from diagnostic biopsies were chosen to have 12 
cases for each grade group (from G1 to G5, grade group 
WHO 2017, see Table 1). 10 of the same cases, two of 
each group grade, also representative tissue blocks from 
radical prostatectomy were analyzed. 5 μm paraffin 
sections deparaffined and antigen retrieved by using a pH9 
Dako Retriever solution, were immunostained by a DAKO 
Autostainer, with EnVisionTM FLEX+ revelation system 
(Dako ColoradoInc, Fort Collins, Colorado, USA). Anti-
human CD44 v9 primary antibody (clone: RV3) was used 
at the optimal dilution 1:1000. Control for the secondary 
antibody was done withdrawing the primary antibody. 
Tissues reactivity was finally compared with the THE 
HUMAN PROTEINATLAS (http://www.proteinatlas.org/). 
We chose to conduct the study on recent occurrences of the 
disease to avoid the possible interference of long paraffin 
embedding on antigen expression or antibody reactivity. 
Been less than 1 year old cases the follow-up clinical 
characterizations were not available yet, we relied on 
Gleason score, the single most important prognostic factor 
in prostate cancer, for indication of disease outcome [45].
Statistical analysis
All numerical data were described as mean ± SEM 
of at least three independent experiments. Data were 
analyzed using the two-tailed student t-test. A probability 
value of 0.05 or less was considered significant.
Abbreviations
PCa: prostate cancer; CRPC: castration-resistant 
PCa; TLRs: Toll-Like Receptors; CD44-neg:CD44-
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PA; SCNC: small cell neuroendocrine carcinoma; FACS: 
Fluorescence Activated Cell Sorter; CSCs: cancer stem 
cells.
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